Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Richard Korsmeyer, PhD

Drug Delivery and Innovation Expert at Korsmeyer Consulting, LLC; Pfizer (ret)


Richard Korsmeyer has been involved with Controlled Release Technology for over 30 years, during which time his work has ranged from basic research to development of commercial products. He was most recently Executive Director, Advanced External Projects in Pharmaceutical Sciences at Pfizer Worldwide R&D where he focused on advanced drug delivery. He has published in the areas of organic synthesis, polymer science, mass transport & diffusion, oral controlled release, parenteral controlled release, supercritical fluid technology, and business. He is an elected member of the National Academy of Engineering (NAE), The Connecticut Academy of Science and Engineering, and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE) and the American Institute of Chemical Engineers (AIChE). He is the author of a popular exponential equation that is widely used to describe data from controlled release experiments, resulting in the most cited paper ever published by the International Journal of Pharmaceutics. Korsmeyer received his BA in chemistry from Vanderbilt, his MS and PhD in chemical engineering from Purdue, and additional training in pharmaceutics at the University of Geneva. In addition to Pfizer, his work experience includes being a laboratory chemist at the Dept of Clinical Pharmacology at Vanderbilt School of Medicine, and an R&D engineer at BFGoodrich. Richard is a member of CRS, ACS, AAPS, and AIChE. He is a member of the Steering Committee for the University of Oxford Centre for Drug Delivery Devices and the Industry Advisory Board for the University of Massachusetts Center for Bioactive Delivery.”

Richard Korsmeyer, PhD's Network

Agenda Sessions